{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","spread":"0.474","upperLimit":"1.00","value":"0.63"},{"groupId":"OG001","lowerLimit":"NA","spread":"0.376","upperLimit":"NA","value":"0.43"}]}],"title":"Pre-dose (Cmin) (n: 34, n: 22)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.68","spread":"19.805","upperLimit":"0.94","value":"23.16"},{"groupId":"OG001","lowerLimit":"NA","spread":"11.889","upperLimit":"NA","value":"13.30"}]}],"title":"2 hours post-dose (C2h) (n: 39, n: 22)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Characterize the PK of exemestane in combination with or without everolimus using Cmin and C2h at week 4 in a small group of patients.","dispersionType":"Standard Deviation","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"OG001","title":"Placebo + Exemestane"}],"paramType":"MEAN","populationDescription":"Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose \\& 2 hours post-dose values for the given time points were analyzed for that time point.","reportingStatus":"POSTED","timeFrame":"predose, 2 hours post-dose","title":"Exemestane Concentrations at Week 4","type":"SECONDARY","unitOfMeasure":"ng/mL"}